NWRD06 administered by electroporation

Phase 2Biologic

NNewish Technology (Beijing) Co., Ltd.

NWRD06 administered by electroporation is one of 4 biologic programs targeting HCC. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HCCRecruiting

HCCPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in HCC

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 2

2 2

Yervoy

Bristol-Myers Squibb

Phase 2

1 3

ABSK-011

AAbbisko Therapeutics Co, Ltd

Phase 2

1 4

NWRD06 administered by electroporation

NNewish Technology (Beijing) Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

HCC

NCT07324304

Clinical

Trials by Indication[1]

HCC2 trials

NWRD06 DNA Plasmid for HCC After Curative Resection.

Recruiting·NNewish Technology (Beijing) Co., Ltd.·Phase 2·NCT07324304·30 enrolled

NWRD06 DNA Plasmid for HCC After Radical Resection

Unknown status·NNewish Technology (Beijing) Co., Ltd.·Phase 1·NCT06088459·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for NWRD06 administered by electroporation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NWRD06 administered by electroporation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NWRD06 administered by electroporation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Newish Technology (Beijing) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: NNewish Technology (Beijing) Co., Ltd.

NWRD06 administered by electroporation

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

HCC2 trials

References

Drug Info

Quick Facts

Related News